Preclinical studies of the CDK7 inhibitor CT7001 in breast cancer models provided evidence that combining CT7001 with tamoxifen (hormonal therapy) resulted in better antitumour activity compared to CT7001 alone [163]. Here, CDK7 is linked to breast carcinoma.